arrow
C

Constance Thibault

Université de Paris Cité
H指数:27
被引数:2,521

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Squamous cell carcinoma of the bladder: Current evidence, therapeutic challenges, and research perspectives from the French AVENTUR group

膀胱鳞状细胞癌:法国AVENTUR小组的当前证据、治疗挑战和研究展望

2026-07-280
OAAI
Real-World Outcomes of First-Line Immune-Based Combination Therapies in Bone-Metastatic Clear Cell Renal Cell Carcinoma

骨转移性透明细胞肾细胞癌中一线免疫为基础的联合疗法真实世界结局

2026-02-011
OA
ALBAN (GETUG-AFU 37): A phase 3, randomized, open-label, international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle invasive bladder cancer (NMIBC)

ALBAN(GETUG-AFU 37):一项关于静脉注射阿替利珠单抗联合膀胱内注射卡介苗(BCG)与单独使用BCG治疗BCG初治高危非肌层浸润性膀胱癌(NMIBC)的3期、随机、开放标签、国际多中心临床试验

2025-10-170
OAAI
The Evolving Landscape of Systemic Immunotherapy for Bacillus Calmette-Guérin–naïve High-risk Non–muscle-invasive Bladder Cancer: At the Edge of a Tsunami?

鲍曼不动杆菌阴性高风险非肌层浸润性膀胱癌的系统免疫治疗发展现状:是否已临近巨变?

2025-08-050
OAAI
Oncological Safety and Diagnostic Yield of Percutaneous Needle-core Biopsies in Upper Tract Urothelial Carcinoma: The UPERCUT Study

上尿路尿路上皮癌经皮针芯活检术的肿瘤学安全性与诊断效能:UPERCUT研究

2025-04-210
PRE
Patient Versus Clinician Reported Symptoms Agreement in Advanced Metastatic Bladder Cancer Patients

晚期转移性膀胱癌患者与临床医生报告症状的一致性

2025-04-210
OAAI
The effect of tumor downsizing on surgical complexity during nephrectomy after immune checkpoint inhibitors for metastatic renal cell carcinoma

免疫检查点抑制剂治疗后,肿瘤缩小对转移性肾细胞癌患者肾切除术手术复杂度的影响

2025-01-021
PRE
Real-world Study of Avelumab First-line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma in France: Overall Results from the Noninterventional AVENANCE Study and Analysis of Outcomes by Second-line Treatment

法国真实世界研究中avelumab作为一线维持治疗用于晚期尿路上皮癌患者的非干预性AVENANCE研究:总体结果及按二线治疗的结局分析

2024-10-010
PREAI
Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study
2024-04-011
PRE
Efficacy and safety of cabozantinib rechallenge in metastatic renal cell carcinoma: A retrospective multicentric study
2023-11-011
PRE
Durvalumab (D) plus /- tremelimumab (T) in combination with dose-dense MVAC (ddMVAC) as neoadjuvant treatment in patients with muscle-invasive bladder carcinoma (MIBC): Results of NEMIO, a randomized phase I-II trial
2023-10-013
OA
Gemcitabine plus platinum-based chemotherapy in combination with bevacizumab for kidney metastatic collecting duct and medullary carcinomas: Results of a prospective phase II trial (BEVABEL-GETUG/AFU24)
2023-06-015
OAAI
Metastatic Sites' Location and Impact on Patient Management After the Introduction of Prostate-specific Membrane Antigen Positron Emission Tomography in Newly Diagnosed and Biochemically Recurrent Prostate Cancer: A Critical Review
2023-04-0112
OA
Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study
2023-03-017
OAAI